
Conference Coverage
about 3 hours ago
Insights Into Advancing Care and Research in Hairy Cell LeukemiaLatest Content

Shorts






Podcasts
Videos
All News

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma.

The MELODY study found music therapy to be effective at relieving the anxiety of cancer survivors.

Denial is a very powerful thing, but it is one that can have serious negative consequences.

After being diagnosed with stage 3 triple-negative breast cancer at 29, Meagan Pettit urges young adults to seek community and define life beyond diagnosis.

Fran Curtis is a survivor of breast, appendix and skin cancer, but said bladder cancer was the toughest.

The story of prevention doesn't end with a surgery date or a clean scan — it unfolds over decades, shaped by habits, choices and vigilance.

In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy.

Experts discuss how better hospice and home care reimbursement can help patients receive compassionate end-of-life care at home.

Get the facts on stage 1 multiple myeloma, including why your doctor may recommend active surveillance and what the latest treatment options are.

The addition of postsurgical Verzenio to endocrine therapy provided a benefit in HR–positive, HER2-negative breast cancer.

Learn what stage 2 ovarian cancer means, how it’s diagnosed, treatment options like surgery and chemotherapy, and key questions to ask your oncologist.

Shopping for prostheses reminded me of being in a very popular old toy store.

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.